Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 29th September 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and UCL to pioneer research into Parkinson's disease
Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's disease.
Vets to explore the possibilities of future prevention and treatment.

A pioneering study into the causes and progression of Parkinson's disease is to be carried out by the Royal Veterinary College (RVC) in collaboration with University College London (UCL).

The news follows a $7 million grant from Aligning Science Across Parkinson's (ASAP), an initiative that fosters collaboration and resources to better understand the underlying causes of this debilitating disease.

Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's. Specifically, the team will investigate the role of the LRRK2 gene - one of the most common genetic causes of the disease and a priority drug target.

Dr Patrick Lewis, Professor of Neuroscience at the RVC, said: “The Aligning Science Across Parkinson’s foundation grants represents a new way of approaching research into Parkinson’s, with the clear goal of accelerating progress in our understanding of this disorder. It is a real privilege to be involved in this initiative.”

Parkinson's is a progressive brain disorder that causes slowness, stiffness, tremors and walking and balance problems. The condition affects more than 130,000 people in the UK alone, and the only current available treatments help to alleviate symptoms, but not slow progression of the disease.

Professor Jonathan Elliott, vice-principal (Research and Innovation) at the RVC, said: “The RVC is delighted to be part of this large collaborative effort to advance treatments for Parkinson’s Disease. Neurodegenerative conditions significantly impact on the quality of life of our ageing human population in the UK and Professor Lewis’ role in this collaboration is exciting in its potential to uncover new drug targets to slow progressive loss of functioning neurons."

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.